These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21405968)

  • 21. Biomarkers in translational research: focus on discovery, development and translation of protein biomarkers to clinical immunoassays.
    Rai AJ
    Expert Rev Mol Diagn; 2007 Sep; 7(5):545-53. PubMed ID: 17892363
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Balancing between hope and hype in biomarker research].
    Bossuyt PM
    Ned Tijdschr Geneeskd; 2011; 155(35):A3859. PubMed ID: 21902852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The ethics of phase 0 oncology trials.
    Abdoler E; Taylor H; Wendler D
    Clin Cancer Res; 2008 Jun; 14(12):3692-7. PubMed ID: 18559585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report.
    Schultz KR; Miklos DB; Fowler D; Cooke K; Shizuru J; Zorn E; Holler E; Ferrara J; Shulman H; Lee SJ; Martin P; Filipovich AH; Flowers ME; Weisdorf D; Couriel D; Lachenbruch PA; Mittleman B; Vogelsang GB; Pavletic SZ
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):126-37. PubMed ID: 16443511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New science-based endpoints to accelerate oncology drug development.
    Kelloff GJ; Sigman CC
    Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical biomarkers of kinase activity: examples from EGFR inhibition trials.
    Krause M; Baumann M
    Cancer Metastasis Rev; 2008 Sep; 27(3):387-402. PubMed ID: 18427731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biomarkers in clinical medicine.
    Chen XH; Huang S; Kerr D
    IARC Sci Publ; 2011; (163):303-22. PubMed ID: 22997869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II clinical trials in oncology: are we hitting the target?
    Ang MK; Tan SB; Lim WT
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
    LoRusso PM; Boerner SA; Seymour L
    Clin Cancer Res; 2010 Mar; 16(6):1710-8. PubMed ID: 20215546
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer biomarkers--an invitation to the table.
    Dalton WS; Friend SH
    Science; 2006 May; 312(5777):1165-8. PubMed ID: 16728629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Translating basic research in cancer patient care.
    Maugeri-Saccà M; De Maria R
    Ann Ist Super Sanita; 2011; 47(1):64-71. PubMed ID: 21430342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials.
    Powers JH
    Pharmacotherapy; 2005 Dec; 25(12 Pt 2):109S-123S. PubMed ID: 16305280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSI.
    Wang SJ
    Pharm Stat; 2007; 6(4):283-96. PubMed ID: 17957727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic and prognostic molecular markers in renal cell carcinoma.
    Tunuguntla HS; Jorda M
    J Urol; 2008 Jun; 179(6):2096-102. PubMed ID: 18423738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy.
    Coughlin CM; Johnston DS; Strahs A; Burczynski ME; Bacus S; Hill J; Feingold JM; Zacharchuk C; Berkenblit A
    Breast Cancer Res Treat; 2010 Nov; 124(1):1-11. PubMed ID: 20803067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Challenges in planning and conducting diagnostic studies with molecular biomarkers.
    Ziegler A; König IR; Schulz-Knappe P
    Dtsch Med Wochenschr; 2013 May; 138(19):e2-24. PubMed ID: 23633283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statistical issues in the validation of prognostic, predictive, and surrogate biomarkers.
    Sargent DJ; Mandrekar SJ
    Clin Trials; 2013 Oct; 10(5):647-52. PubMed ID: 23983158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations.
    Dobbin KK; Cesano A; Alvarez J; Hawtin R; Janetzki S; Kirsch I; Masucci GV; Robbins PB; Selvan SR; Streicher HZ; Zhang J; Butterfield LH; Thurin M
    J Immunother Cancer; 2016; 4():77. PubMed ID: 27891226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.